915390-10-2 Usage
General Description
The chemical compound ((3R,4S)-4-(3-Fluorophenyl)pyrrolidin-3-yl)methanol is a chiral molecule containing a pyrrolidine ring with a 3-fluorophenyl group attached to it. It is classified as a pyrrolidine derivative and a secondary alcohol. ((3R,4S)-4-(3-Fluorophenyl)pyrrolidin-3-yl)methanol has the potential to exhibit biological activity due to its structural features, and it may be used as a building block in the synthesis of various pharmaceuticals and organic compounds. The stereochemistry of the molecule, with the (3R,4S) configuration, is important for its reactivity and interactions with other molecules. Further research and analysis are needed to fully understand the properties and potential applications of this chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 915390-10-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,5,3,9 and 0 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 915390-10:
(8*9)+(7*1)+(6*5)+(5*3)+(4*9)+(3*0)+(2*1)+(1*0)=162
162 % 10 = 2
So 915390-10-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H14FNO/c12-10-3-1-2-8(4-10)11-6-13-5-9(11)7-14/h1-4,9,11,13-14H,5-7H2/t9-,11-/m1/s1
915390-10-2Relevant articles and documents
PYRROLIDINE DERIVATIVE OR SALT THEREOF
-
Page/Page column 52, (2008/06/13)
[PROBLEMS] To provide a compound which can be used for the treatment of a disease associated with a calcium-sensing receptor (CaSR), particularly hyperparathyroidism. [MEANS FOR SOLVING PROBLEMS] It is found that a novel pyrrolidine derivative having an aminomethyl group substituted by an arylaklyl group or the like or a salt thereof has an excellent CaSR agonistic modulation effect and also has an excellent selectivity in the inhibition of CYP2D6 which may cause a drug-drug interaction. Thus, the novel pyrrolidine derivative is useful as a therapeutic agent for a disease associated with CaSR (e.g., hyperparathyroidism, renal osteodystrophy and hypercalcemia).
